Compounded Semaglutide vs Tirzepatide: How to Choose

See if you qualify in 5 minutes →
5-minute questionnaire · reviewed by a licensed clinician · The Nouri Promise: a full refund on the 3-month and 6-month plans if you're not satisfied in your first 30 days · cancel anytime

The choice between compounded semaglutide vs tirzepatide is not simply a question of which medication may lead to greater weight loss. It is a decision about clinical fit, tolerability, medical history, access, and the quality of care surrounding the prescription. The right answer is personal, and it deserves more than a rushed checkout screen.

Both medications can be part of a thoughtful approach to chronic weight management. They also have meaningful differences. A clinician should assess those differences alongside your goals, current health conditions, medication history, and ability to maintain the habits that support treatment.

At a glance

	Compounded semaglutide	Compounded tirzepatide
Mechanism	GLP-1 receptor agonist	Dual GIP + GLP-1 receptor agonist
Branded-trial results (not compounded outcomes)	~14% average body-weight loss at 72 weeks (Wegovy arm, SURMOUNT-5)	~20% average body-weight loss at 72 weeks (Zepbound arm, SURMOUNT-5)
Common side effects	Overlapping: nausea, constipation, diarrhea, vomiting, reflux, fatigue — mostly during dose escalation
FDA status	Compounded versions are not FDA-approved (branded versions Wegovy/Ozempic and Zepbound/Mounjaro are)
Notable cautions	MTC/MEN 2 history, pancreatitis, pregnancy, blood-sugar medications; tirzepatide can affect oral-contraceptive absorption during dose increases
Nouri all-inclusive price	$120/mo on the 6-month plan	$175/mo on the 6-month plan

Trial figures describe the FDA-approved branded medications under clinical-trial conditions — they are not outcomes of compounded products or of the Nouri program, and individual results vary. Information current as of July 2026.

Compounded Semaglutide vs Tirzepatide: The Core Difference

Semaglutide works by mimicking GLP-1, a naturally occurring hormone involved in appetite regulation, digestion, and blood sugar management. It can help people feel full sooner, stay satisfied longer, and reduce persistent food noise. GLP-1 activity also slows gastric emptying, which is one reason meals may feel more filling during treatment. (The molecule's effects were characterized in trials such as STEP 1, published in the New England Journal of Medicine — research on the branded medication, not on compounded products.)

Tirzepatide acts on GLP-1 and a second receptor called GIP, or glucose-dependent insulinotropic polypeptide. This dual action may offer additional metabolic effects for some patients. In clinical studies of FDA-approved versions — including the SURMOUNT-5 head-to-head trial of Zepbound versus Wegovy, where average weight loss was roughly 20% versus 14% of body weight at 72 weeks — tirzepatide has generally produced greater average weight loss than semaglutide. That average, however, is not a promise for any individual, and it describes the branded molecules, not compounded formulations. For a data-focused comparison of the branded medications themselves, see tirzepatide vs semaglutide.

For some people, semaglutide is an effective, well-tolerated place to begin. Others may be candidates for tirzepatide because of their clinical profile or prior response to treatment. Neither option should be treated as a shortcut or a cosmetic purchase. These are prescription medications that require ongoing medical judgment.

What "Compounded" Means

A compounded medication is prepared by a licensed compounding pharmacy for an individual patient when a clinician determines it is medically appropriate. Compounded drugs are not FDA-approved, meaning the FDA does not review them for safety, effectiveness, or quality before they are dispensed.

That distinction matters. It does not mean every compounded medication is inherently inappropriate. It means the pharmacy, sourcing practices, formulation, and clinical oversight deserve close attention.

Compounding may be permitted under specific federal and state conditions, including certain circumstances involving drug shortages and patient-specific prescriptions — the FDA's questions-and-answers page on compounding explains the framework. Those conditions can change. A reputable care team should confirm whether compounding is appropriate and lawful at the time of prescribing, rather than treating availability as fixed.

Patients should also know exactly what they are receiving. The active ingredient should be clearly identified, the prescription label should include dosing instructions, and the medication should come from a properly licensed pharmacy. Be cautious with products described vaguely as "semaglutide-like," "GLP-1 support," or research-grade peptides. Prescription weight care should not depend on ambiguity.

A note on formulation quality

The quality of a compounded medication is inseparable from the quality of its pharmacy partner. Ask whether the pharmacy is appropriately licensed, whether the medication is prescribed following a clinician review, and how it is shipped and stored. Cold-chain handling, clear labeling, sterile preparation standards, and responsive pharmacy support are practical safeguards, not luxuries.

A clinician should also review the specific formulation. The FDA has raised concerns about certain semaglutide salt forms that differ from the semaglutide used in FDA-approved medications. Patients should not be expected to sort through those distinctions alone.

How the Experience May Feel Different

The most immediate difference patients notice is often appetite change. Both medications can reduce hunger and make portions feel naturally smaller. Tirzepatide may feel more potent for some people, while others find semaglutide provides enough appetite support with a treatment experience that suits them well.

Side effects overlap. Nausea, constipation, diarrhea, vomiting, abdominal discomfort, reflux, fatigue, and reduced appetite can occur with either medication, particularly during dose escalation. Eating slowly, prioritizing protein, staying hydrated, and following a clinician-directed titration plan can make a meaningful difference.

More medication is not always better medication. Escalating too quickly can make side effects harder to manage and may disrupt the consistency that long-term progress requires. The best dose is not necessarily the highest dose. It is the dose that balances benefit, comfort, nutrition, and safety under clinical supervision.

There are also differences that cannot be predicted from a comparison chart. One patient may respond well to semaglutide after struggling with another medication. Another may find tirzepatide better aligned with their metabolic needs. Response is individual, which is why continuing care matters after the first prescription is written.

Who May Need a Different Approach

GLP-1-based treatment is not right for everyone. A clinician should carefully review personal and family history before prescribing. These medications are generally avoided in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 — contraindications listed on the FDA-approved prescribing label for branded semaglutide.

A history of pancreatitis, gallbladder disease, severe gastrointestinal disease, kidney concerns, diabetic retinopathy, or eating disorders may also shape the treatment decision. So can pregnancy, plans to become pregnant, breastfeeding, and the use of medications that affect blood sugar. People taking insulin or sulfonylureas, for example, may need closer monitoring because blood sugar can fall too low.

Tirzepatide can affect the absorption of oral contraceptives when starting treatment and during dose increases, a caution noted on the branded tirzepatide prescribing label. This is the kind of detail that makes a real clinician relationship essential. Your care should account for the rest of your life, not just a number on the scale.

Choosing Based on More Than the Scale

When comparing compounded semaglutide vs tirzepatide, begin with your clinical eligibility and then consider your priorities. Do you have a history of significant gastrointestinal sensitivity? Are you managing blood sugar concerns? Have you used a GLP-1 medication before? Is your goal focused on weight reduction, metabolic markers, or both? Would a gradual, measured approach help you build routines that last?

Cost and continuity also belong in the conversation. A lower introductory price has limited value if it excludes follow-up care, changes without warning, or leaves you navigating side effects alone. Weight management is ongoing care. The experience should include access to qualified clinicians, transparent pricing, dependable medication fulfillment, and guidance that helps protect muscle mass and nutritional intake as weight changes.

Medication can make healthy choices more accessible. It cannot replace them. Adequate protein, resistance training when appropriate, daily movement, sleep, hydration, and realistic meal structure help preserve the progress medication supports. These practices are not a test of willpower. They are part of sound medical weight care.

The Standard to Look For

A premium telehealth experience should still feel like medicine. That means a clinician-led eligibility review, an honest discussion of risks and alternatives, clear instructions for treatment, and follow-up that continues beyond shipment day. Privacy and convenience matter, but they should never come at the expense of clinical standards.

At Nouri, care is designed around that balance: discreet home delivery, physician-guided treatment, and personalized nutrition and movement support within one considered program. The intention is not to make weight care feel transactional. It is to make it easier to sustain.

The best choice may be compounded semaglutide, compounded tirzepatide, an FDA-approved option, or no GLP-1 medication at all. A careful clinician will not force a predetermined answer. They will help you choose a path that respects your health, your privacy, and the life you want to live.

How Nouri offers both medications

Nouri's program includes both options at one all-inclusive price: the compounded GLP-1 medication (when prescribed), a personalized nutrition plan, and a movement plan — the same price at any dose, with no separate membership fee. Compounded semaglutide is $120/month on the six-month plan ($720 every 6 months), $145/month on the three-month plan ($435 every 3 months), or $175/month billed monthly. Compounded tirzepatide is $175/month on the six-month plan ($1,050 every 6 months), $199/month on the three-month plan ($597 every 3 months), or $225/month billed monthly.

Medication is prepared by named, state-licensed 503A compounding pharmacies (Jungle Jim's Pharmacy, Fairfield, OH, and VialsRX). A U.S.-licensed clinician reviews your health intake and prescribes the medication — semaglutide, tirzepatide, or neither — only if clinically appropriate; not all applicants qualify. Nouri is LegitScript-certified and available in all 50 states. (Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as the brand-name drugs.) The Nouri Promise: if you're not satisfied in your first 30 days, you get a full refund — available on 3-month and 6-month plans.

Start your 5-minute assessment →
5-minute questionnaire · reviewed by a licensed clinician · The Nouri Promise: full refund on 3-month and 6-month plans within 30 days · cancel anytime

Related comparison guides

• Tirzepatide vs Semaglutide: The Branded Head-to-Head Data
• Brand-Name vs Compounded GLP-1
• Compounded Semaglutide vs Wegovy
• Compounded Tirzepatide vs Zepbound
• What Does a GLP-1 Cost in 2026?

Frequently asked questions

Which works better, compounded semaglutide or compounded tirzepatide?

There is no head-to-head trial of the compounded versions. In the SURMOUNT-5 trial of the FDA-approved branded medications (Zepbound vs Wegovy), tirzepatide produced greater average weight loss than semaglutide over 72 weeks — about 20% versus 14% of body weight. Those results reflect the branded molecules under trial conditions, not compounded products, and individual response varies. The better choice for you depends on your health history, tolerability, and a licensed clinician's evaluation.

Are compounded semaglutide and tirzepatide FDA-approved?

No. Compounded semaglutide and compounded tirzepatide are not FDA-approved and are not the same as, or therapeutically equivalent to, the brand-name drugs (Wegovy, Ozempic, Zepbound, Mounjaro). They are prepared by licensed compounding pharmacies for individual patients and may be prescribed when a clinician determines compounded treatment is appropriate.

Do semaglutide and tirzepatide have the same side effects?

They overlap heavily. Nausea, constipation, diarrhea, vomiting, abdominal discomfort, reflux, fatigue, and reduced appetite can occur with either medication, most often during dose increases. A clinician-directed titration plan, eating slowly, prioritizing protein, and staying hydrated can make side effects easier to manage.

Can I switch from semaglutide to tirzepatide, or the reverse?

Sometimes, under clinical supervision. A clinician may consider a switch based on your response, tolerability, or goals — and will set an appropriate starting dose for the new medication rather than carrying your old dose over. Never switch or adjust GLP-1 medications on your own.

How much do compounded semaglutide and tirzepatide cost?

Prices vary by provider and what the price includes. Nouri's all-inclusive program (medication when prescribed, plus a nutrition plan and a movement plan, same price at any dose) is $120/month for compounded semaglutide on the six-month plan and $175/month for compounded tirzepatide on the six-month plan.

Sources & references

1. Aronne LJ et al., "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity" (SURMOUNT-5), New England Journal of Medicine, 2025 — head-to-head research on the branded medications; not a study of compounded products (Tier 1)
2. Wilding JPH et al., "Once-Weekly Semaglutide in Adults with Overweight or Obesity" (STEP 1), New England Journal of Medicine, 2021 — research on the branded semaglutide molecule (Tier 1)
3. Jastreboff AM et al., "Tirzepatide Once Weekly for the Treatment of Obesity" (SURMOUNT-1), New England Journal of Medicine, 2022 — research on the branded tirzepatide molecule (Tier 1)
4. FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — U.S. Food and Drug Administration (Tier 1)
5. FDA: Compounding and the FDA — Questions and Answers — U.S. Food and Drug Administration (Tier 1)
6. Wegovy FDA Prescribing Label (2025) — U.S. Food and Drug Administration (Tier 1)
7. Zepbound FDA Prescribing Label (2025) — U.S. Food and Drug Administration (Tier 1)
8. Nouri program information — joinnouri.com (July 2026)

Medically reviewed by Amber Patel, MD. Nouri content is reviewed by licensed clinicians and updated as guidance changes. Author: Nouri Editorial Team.

This article is general education, not medical advice — eligibility and prescribing decisions are made by a licensed clinician based on your individual evaluation. Ozempic®, Wegovy®, and Rybelsus® are registered trademarks of Novo Nordisk; Mounjaro® and Zepbound® are registered trademarks of Eli Lilly. Nouri is not affiliated with, endorsed by, or sponsored by these companies. Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as, or therapeutically equivalent to, the brand-name drugs. Clinical-trial results cited describe the FDA-approved branded medications and are not outcomes of compounded products or of the Nouri program; individual results vary. Telehealth requirements vary by state and may change. Pricing is current as of July 2026 — see joinnouri.com/weight-loss for current terms.